Clinical Trial Update: Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Dynamic Contrast-Enhanced MRI in combination with Bevacizumab and Irinotecan for malignant glioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Duke University | Conditions: Brain and Central Nervous System Tumors | Phase 2 | Status: COMPLETED